PopVax Private, Ltd.
PopVax is an Indian full-stack biotechnology company developing novel mRNA vaccines and therapeutics using computational protein design. Founded in late 2021, it focuses on creating innovative vaccine platforms and has achieved significant preclinical success, including a next-generation COVID-19 vaccine that elicits potent immune responses. The company aims to make vaccines accessible globally, especially in developing countries, and is involved in cutting-edge research, clinical trials, and collaborations with government agencies and foundations.
Industries
Nr. of Employees
small (1-50)
Products
Next-generation mRNA-LNP COVID-19 vaccine candidate
Preclinical vaccine candidate using a next-generation mRNA architecture delivered in LNPs; selected for inclusion in a government-sponsored Phase I program to evaluate safety and immunogenicity in humans.
Seasonal influenza vaccine program for dissolvable microarray patch delivery
Influenza vaccine program designed for self-administered dissolvable microarray patch delivery; recipient of a government prize award to develop patch-delivered formulation.
mRNA-encoded immunogen display and LNP delivery platforms
Platform technologies comprising an mRNA-encoded immunogen display architecture for VLP presentation and an LNP delivery platform incorporating designed ionizable lipids to enable vaccine and therapeutic development.
Next-generation mRNA-LNP COVID-19 vaccine candidate
Preclinical vaccine candidate using a next-generation mRNA architecture delivered in LNPs; selected for inclusion in a government-sponsored Phase I program to evaluate safety and immunogenicity in humans.
Seasonal influenza vaccine program for dissolvable microarray patch delivery
Influenza vaccine program designed for self-administered dissolvable microarray patch delivery; recipient of a government prize award to develop patch-delivered formulation.
mRNA-encoded immunogen display and LNP delivery platforms
Platform technologies comprising an mRNA-encoded immunogen display architecture for VLP presentation and an LNP delivery platform incorporating designed ionizable lipids to enable vaccine and therapeutic development.
Services
On-site integrated research and GMP-capable manufacturing to support process development and production of clinical trial material.
Machine learning-enabled computational design workflows to generate and prioritize protein immunogen candidates.
Wet-lab vaccine development, high-throughput immunology experiments, and preclinical testing to measure antibody responses and other immunogenicity endpoints.
Development of analytical assays and characterization methods to support product development and release testing.
Manufacturing and process activities aimed at enabling early-phase human testing and collaboration with trial sponsors and public health programs.
On-site integrated research and GMP-capable manufacturing to support process development and production of clinical trial material.
Machine learning-enabled computational design workflows to generate and prioritize protein immunogen candidates.
Wet-lab vaccine development, high-throughput immunology experiments, and preclinical testing to measure antibody responses and other immunogenicity endpoints.
Development of analytical assays and characterization methods to support product development and release testing.
Manufacturing and process activities aimed at enabling early-phase human testing and collaboration with trial sponsors and public health programs.
Expertise Areas
- Computational protein design
- Machine learning for protein and immunogen design
- mRNA vaccine design and LNP delivery
- Integrated R&D and small-scale GMP manufacturing
Key Technologies
- mRNA-LNP delivery
- Ionizable lipid design for LNPs
- mRNA-encoded virus-like particle (VLP) immunogen display
- Machine learning-driven protein design
News & Updates
The US National Institute of Allergy and Infectious Diseases will conduct and sponsor a Phase I trial of PopVax’s COVID-19 vaccine, expected to begin in early 2025, to evaluate safety and immunogenicity.
PopVax announced $1.15 million in funding from the Gates Foundation for developing thermostable mRNA delivery formulations.
PopVax was awarded $2 million as a winner of the BARDA Patch Forward Prize for its seasonal influenza vaccine based on a novel mRNA-encoded immunogen display architecture delivered via a dissolvable microarray patch.
The US National Institute of Allergy and Infectious Diseases will conduct and sponsor a Phase I trial of PopVax’s COVID-19 vaccine, expected to begin in early 2025, to evaluate safety and immunogenicity.
PopVax announced $1.15 million in funding from the Gates Foundation for developing thermostable mRNA delivery formulations.
PopVax was awarded $2 million as a winner of the BARDA Patch Forward Prize for its seasonal influenza vaccine based on a novel mRNA-encoded immunogen display architecture delivered via a dissolvable microarray patch.